Description
GDC-0032 inhibits PI3K, exhibiting anticancer chemotherapeutic activity by inhibiting tumor growth in various animal models. This compound also induces G0/G1 phase cell cycle arrest in models of uterine serous carcinoma.
GDC-0032
Product ID G1308
Cas No. 1282512-48-4
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1282512-48-4 |
|---|---|
| Purity | ≥98% |
| Formula | C24H28N8O2 |
| Formula Wt. | 460.53 |
| IUPAC Name | 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide |
| Synonym | GDC0032, Taselisib |
| Solubility | DMSO 70 mg/mL warmed (151.99 mM) Water Insoluble Ethanol Insoluble warmed |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Lopez S, Schwab CL, Cocco E, et al. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol. 2014 Nov;135(2):312-7. PMID: 25172762.
Ndubaku CO, Heffron TP, Staben ST, et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem. 2013 Jun 13;56(11):4597-610. PMID: 23662903.